Dr. Landgren on Managing Toxicities of Multiple Myeloma Treatment

C. Ola Landgren, MD, PhD
Published: Monday, Apr 03, 2017



C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.

While every drug has its own levels of efficacy and toxicity, Landgren says management of toxicities in multiple myeloma treatment comes down to oral clinical exam, monitoring labs and being aware of the safety profiles of each drug.

Physicians should be informing their patients about side effects throughout treatment, as every case is unique and dosage might need to be altered to suit the individual needs of a given patient.
 


C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.

While every drug has its own levels of efficacy and toxicity, Landgren says management of toxicities in multiple myeloma treatment comes down to oral clinical exam, monitoring labs and being aware of the safety profiles of each drug.

Physicians should be informing their patients about side effects throughout treatment, as every case is unique and dosage might need to be altered to suit the individual needs of a given patient.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x